Edition:
United States

Basilea Pharmaceutica AG (BPMUF.PK)

BPMUF.PK on OTC Markets Group

82.71USD
--
Change (% chg)

-- (--)
Prev Close
$82.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
137
52-wk High
$92.55
52-wk Low
$66.55

Latest Key Developments (Source: Significant Developments)

Basilea says distribution agreement with Cardiome
Tuesday, 12 Sep 2017 01:15am EDT 

Sept 12 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL.‍BASILEA WILL RECEIVE AN UPFRONT PAYMENT OF CHF 5 MILLION​.CARDIOME GRANTED EXCLUSIVE LICENSE TO COMMERCIALIZE CEFTOBIPROLE IN MORE THAN 30 COUNTRIES IN EUROPE AND IN ISRAEL.  Full Article

Basilea reports significant progress on partnering and development programs
Thursday, 10 Aug 2017 01:18am EDT 

Aug 10 (Reuters) - Basilea Pharmaceutica AG ::Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs.  Full Article

Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​
Thursday, 10 Aug 2017 01:15am EDT 

Aug 10 (Reuters) - BASILEA PHARMACEUTICA AG ::‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​.‍COMPLETED LICENSE AGREEMENT WITH PFIZER FOR CRESEMBA IN EUROPE​.CHF 253.1 MILLION IN CASH AND INVESTMENTS AS OF JUNE 30, 2017 AND A SIGNIFICANTLY REDUCED OPERATING LOSS OF CHF 17.7 MILLION IN FIRST HALF-YEAR (H1 2016: CHF 24.8 MILLION; -29%).‍REPORTED CHF 253.1 MILLION IN CASH AND INVESTMENTS AS OF JUNE 30, 2017​.UPDATES ITS FINANCIAL GUIDANCE FOR 2017.‍H1 NET LOSS NARROWS TO 20.6 CHF MILLION​.‍NOW ANTICIPATES ITS 2017 PRODUCT SALES TO BE APPROXIMATELY CHF 13 MILLION, AND A PARTICIPATION IN PARTNER SALES THROUGH ROYALTIES OF APPROXIMATELY CHF 15 MILLION​.TOTAL OPERATING EXPENSES FOR 2017, NET OF ANTICIPATED BARDA REIMBURSEMENTS, ARE ESTIMATED AT CHF 9-10 MILLION ON AVERAGE PER MONTH.  Full Article

Pfizer to have exclusive rights to distribute, commercialize CRESEMBA in Europe
Wednesday, 14 Jun 2017 01:20pm EDT 

June 14 (Reuters) - Pfizer Inc ::Pfizer receives exclusive commercialization rights in Europe for CRESEMBA, a novel treatment for potentially life-threatening fungal infections among immunocompromised patients.Pfizer will have exclusive rights to distribute and commercialize CRESEMBA in Europe, including Austria, France, Germany, Italy and UK.Pfizer will be responsible for additional CRESEMBA launches, predominantly in Europe, which are expected throughout 2017 and 2018​.Basilea will remain marketing authorization holder for CRESEMBA in European Union.  Full Article

Basilea announces license agreement with Pfizer for antifungal Cresemba
Wednesday, 14 Jun 2017 01:16pm EDT 

June 14 (Reuters) - Basilea Pharmaceutica AG ::Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey And Israel.Under terms of agreement, Basilea will receive an upfront payment of CHF 70 million.Basilea will receive royalties in mid-teen range on Pfizer's sales in territory.Says considering collaboration with Pfizer, Basilea's total product sales are expected at approximately CHF 11 million for year.Will be eligible to get up to $427 million in additional payments upon achievement of pre-specified regulatory and sales milestones​.Contribution from transaction in 2017 is estimated at approximately CHF 6 million through revenue recognition and royalty payments.Says contribution from transaction in 2017 is estimated at about CHF 6 million through revenue recognition and royalty payments.Subject to deal closing, sees financial guidance for 2017 to improve.Pfizer will have right to manufacture isavuconazole and to exclusively commercialize drug in Europe, Russia, Turkey And Israel.Cresemba sales after deal closing will be booked by Pfizer.Subject to deal closing, co sees total operating expenses reduced to approximately CHF 9-10 million on average per month for 2017.Subject to deal closing, sees operating loss of approximately CHF 2-3 million on average per month for 2017.  Full Article

Basilea announces distribution agreement with Avir Pharma for Cresemba And Zevtera in Canada
Wednesday, 14 Jun 2017 01:15am EDT 

June 14 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH AVIR PHARMA INC. FOR CRESEMBA (ISAVUCONAZOLE) AND ZEVTERA (CEFTOBIPROLE) IN CANADA.BASILEA WILL RECEIVE AN UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS UPON ACHIEVEMENT OF REGULATORY AND COMMERCIAL MILESTONES.  Full Article

Basilea Pharmaceutica awarded $54.8 mln of additional funding by BARDA
Tuesday, 13 Jun 2017 01:15am EDT 

June 13 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA AWARDED USD 54.8 MILLION OF ADDITIONAL FUNDING BY BARDA TO SUPPORT PHASE 3 DEVELOPMENT OF CEFTOBIPROLE.‍TOTAL POTENTIAL FUNDING OF UP TO APPROXIMATELY USD 108 MILLION UNDER CONTRACT WILL ENABLE BASILEA TO CONDUCT TWO CLINICAL PHASE 3 STUDIES​.‍TOTAL VALUE OF CONTRACT COULD REACH APPROXIMATELY USD 108 MILLION OVER A PERIOD OF 4.5 YEARS IF PRE-DEFINED MILESTONES ARE MET​.  Full Article

Basilea Pharmaceutica announces clinical study agreement with Adult Brain Tumor Consortium
Monday, 12 Jun 2017 01:15am EDT 

June 12 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM TO EXPLORE BAL101553 IN NEWLY DIAGNOSED GLIOBLASTOMA.  Full Article

Basilea shareholders approve resolutions proposed by the board at the general meeting of shareholders
Thursday, 27 Apr 2017 12:32pm EDT 

April 27 (Reuters) - Basilea Pharmaceutica Ag :Basilea shareholders approve all resolutions proposed by the board of directors at the ordinary general meeting of shareholders.Shareholders also approved increase of authorized share capital..Basilea says shareholders elected Dr. Nicole Onetto as new member of board and re-elected Domenico Scala as chairman.  Full Article

Basilea Pharmaceutica: agreement with FDA regarding ceftobiprole
Friday, 21 Apr 2017 01:16am EDT 

April 21 (Reuters) - Basilea Pharmaceutica AG ::Basilea announces agreement with FDA on special protocol assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections.Initiation of ceftobiprole pivotal phase 3 clinical program under barda contract anticipated within next three to six months.  Full Article

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel